Clinical trial · Observational
A Registry-study of ELZONRIS in Participants With BPDCN
Post-Authorisation Registry of ELZONRIS (Tagraxofusp) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT07785154CI-TRIAL-00123747recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Blastic Plasmacytoid Dendritic Cell Neoplasm | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tagraxofusp | Drug | Tagraxofusp | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Primary Cohort: Previously Untreated
- description
- Adult participants with BPDCN prescribed tagraxofusp as a first-line treatment.
- interventionNames
- Drug: Tagraxofusp
- label
- Exploratory Cohort: Relapsed/Refractory
- description
- Adult participants with BPDCN prescribed tagraxofusp who are relapsed/refractory to prior treatment.
- interventionNames
- Drug: Tagraxofusp
Primary outcomes (2)
- measure
- Number of Participants Achieving Complete Response After 3 Months (+/- 1 month) of Treatment
- timeFrame
- Up to Month 4
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: * Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56). * Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment. Key Exclusion Criteria: * Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported. * Participating in an interventional clinical trial at the time of ICF signature. * Known allergic reactions to components of tagraxofusp. Note: Other protocol-specified criteria apply.
References
Publications (0)
Data not yet available
No reference posted for this study.